NCT01258101View on ClinicalTrials.gov

A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3

PHASE4CompletedINTERVENTIONAL
Enrollment

395

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Hepatitis C, Chronic
Interventions
DRUG

peginterferon alfa-2a [Pegasys]

180 mcg sc weekly, 24 weeks

DRUG

peginterferon alfa-2a [Pegasys]

180 mcg sc weekly, 16 weeks

DRUG

ribavirin

800 mg orally daily

DRUG

ribavirin

400 mg orally daily

Trial Locations (18)

1030

Vienna

1090

Vienna

1100

Vienna

1130

Vienna

1140

Vienna

1160

Vienna

1220

Vienna

2700

Wiener Neustadt

4010

Linz

4020

Linz

4600

Wels

4910

Ried-innkreis

5020

Salzburg

5110

Oberndorf

6020

Innsbruck

8036

Graz

8112

Gratwein

9500

Villach

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01258101 - A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3 | Biotech Hunter | Biotech Hunter